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Low Back Pain During Streptokinase Infusion
Case Report
We report the case of a 57-year-old male patient with
severe low back pain during streptokinase infusion admi-
nistered to treat typical chest pain and elevation of the ST
segment in the inferior wall. We reviewed the literature,
emphasizing the differential diagnosis, the pathophysio-
logy, and management of the event.
The treatment of acute myocardial infarction in its first
hours of evolution is currently based on reperfusion of the culprit
artery, as soon as possible, with a fibrinolytic agent or primary
angioplasty. Streptokinase is one of the fibrinolytic agents
currently used. It is a highly active thrombolytic substance
produced by strains of the group C beta-hemolytic streptococci
according to the Lancefield classification. Of the most common
adverse effects resulting from the use of streptokinase, we may
cite hypotension, bleeding at the sites of puncture, urticaria,
redness, nausea, vomiting, and headache 1. Hemorrhagic stroke
is one of the most severe side effects, and it occurs in 0.3% to 1%
of the patients using that thrombolytic agent.
We report another side effect occurring during strep-
tokinase infusion, low back pain, which has already been
cited in some case reports since 1990.
Case Report
The patient is a 57-year-old male with diabetes and
chronic renal insufficiency, who was admitted to the Coro-
nary Unit of the Hospital São Paulo of the Escola Paulista
de Medicina of the Universidade Federal de São Paulo (UNI-
FESP) complaining of typical chest pain for 4 hours. His
electrocardiogram showed elevation of the ST segment in
the inferior wall. On physical examination, the patient was
hemodynamically stable, his cardiac and pulmonary aus-
cultations were normal, and his peripheral pulses were
palpable and symmetric.
Infusion of the thrombolytic agent was initiated, and,
after receiving 130,000 U, the patient began to complain of
severe bilateral low back pain, which he characterized as ex-
cruciating and radiating to the hypogastric region. The
thrombolytic infusion was suspended for 5 minutes. The
physical examination of the patient at that time remained unal-
tered with maintenance of the blood pressure in his 4 limbs,
palpable and symmetric peripheral pulses, and normal
neurological examination. Based on the normal physical
examination and considering the benefits of continuing the
thrombolytic agent, we decided to take the chance that the
back pain would not recur and maintained the thrombolytic
infusion. When restarting the drug, the patient complained
again of low back pain. We initiated analgesia with 5mg of a
decimal solution of meperidine, maintained thrombolytic
infusion at a lower pace, and from the 12th minute of infusion
on, the patient began to report significant relief in low back
pain, and no longer complained of chest pain. During the rest
of the infusion, the patient still complained of low back pain,
which was mild and bearable. Ten minutes after the end of
infusion, the patient no longer complained of any pain.
On the same day, the patient underwent abdominal
echography, which revealed signs of chronic parenchymal
nephropathy, but no signs of aortic dissection or retroperi-
toneal hemorrhage.
Discussion
In 1990, Shah and Taylor 2, for the first time, reported 3
cases of low back pain during streptokinase infusion. The
first patient was a 54-year-old hypertensive male, who was
admitted to the hospital with severe chest pain and electro-
cardiographic findings of infarction in the anterior wall. The
patient received acetylsalicylic acid, and streptokinase was
started. After infusion of 350,000 U, the patient reported se-
vere central low back pain; therefore, the thrombolytic infu-
sion was suspended. Five minutes after drug suspension,
the patient no longer complained of low back pain.
The 2nd patient was a 35-year-old diabetic male com-
plaining of chest pain for the previous 2 hours. His electro-
cardiogram showed anterolateral infarction. After receiving
300,000 U of streptokinase, the patient complained of severe
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low back pain with irradiation to the lower limbs. The throm-
bolytic agent was suspended, and the pain was relieved in 5
minutes.
The 3 rd patient was a 64-year-old male with antecedent
stable angina, who reported excruciating low back pain after
receiving 255,000 U of streptokinase, the drug being then
suspended. The patient was medicated with hydrocorti-
sone, which significantly improved his low back pain. The
thrombolytic agent was restarted after the physical exami-
nation proved unchanged.
In this 1st report, the authors only reintroduced the
thrombolytic agent with a corticoid in the 3 rd patient, becau-
se they considered the event to be an allergic manifestation
to the drug. Shah et al2 did not report whether the patients
were further investigated.
In 1991, Dickinson and Rosser 3 reported the cases of 2
patients with low back pain during streptokinase infusion.
Their 1 st patient was a 74-year-old hypertensive male with
chest pain and an electrocardiogram compatible with infarc-
tion in the inferior wall. After administration of 150,000 U of
streptokinase, the patient experienced severe low back
pain, which subsided after intravenous administration of
5mg of morphine and suspension of the thrombolytic agent.
Their 2nd patient was a 73-year-old diabetic female with
chest pain, dyspnea, and an electrocardiogram compatible
with infarction in the lateral wall. After infusion of 200,000 U
of streptokinase, the patient complained of severe low back
pain, the thrombolytic agent being then suspended. The
pain spontaneously disappeared within 10 minutes. The
patient evolved with the appearance of a rash on her lower
limbs, which led the authors to confirm the pathophysiolo-
gy suggested by Shah and Taylor that the phenomenon
could be an allergic manifestation.
In the same year, Porter and Nikoletatos 4 reported the
case of a 50-year-old female with typical chest pain and an
electrocardiogram compatible with infarction in the inferior
wall, who, after starting streptokinase infusion, began to
complain of symptoms similar to those already cited. The
thrombolytic agent was suspended.
In October 1992, Lear et al 5 reported on 5 patients with
low back pain during streptokinase infusion. In 3 of these
patients, the pain was eliminated with 2.5mg of intravenous
morphine, streptokinase being maintained. No adverse
effect was observed in those who finished infusion. Their 4 th
patient complained of the reappearance of the pain after re-
introduction of the drug, whose infusion was then suspen-
ded. In the 5 th patient, streptokinase was replaced by tissue
plasminogen activator, and the patient no longer complai-
ned of pain. The authors emphasized that no patient deve-
loped a rash, hypotension, urticaria, edema glottidis, or any
other symptom suggesting an allergic manifestation. As all
5 patients had enzyme findings compatible with acute myo-
cardial infarction, the authors raised the hypothesis that the
low back pain could have resulted from an effect secondary
to lysis of an intracoronary thrombus.
In the same year, new reports on this effect of streptoki-
nase appeared, but with different clinical characteristics. Ma-
hadeva and Siklos 6 reported 2 cases. The 1st patient had an
electrocardiogram compatible with infarction in the lateral wall,
and, after 30 minutes of streptokinase infusion, he complained
of severe interscapular pain. The thrombolytic agent was
suspended, and the pain subsided spontaneously within 5
minutes. The 2nd patient was a 60-year-old female with clinical
and electrocardiographic findings compatible with infarction,
who, after 15 minutes of streptokinase infusion, complained of
severe pain in the inferior region of the hypogastrium. In that
report 6, the authors suggested that streptokinase could not
only cause low back pain, but also abdominal pain.
Still in 1992, a new report showed an evolution diffe-
rent from that reported until that time. Jenkins 7 reported the
case of a patient with low back pain during streptokinase in-
fusion, who had gross hematuria at the beginning of infusi-
on and evolved to microscopic hematuria in the 12 subse-
quent hours. The thrombolytic agent was suspended and
imaging examinations showed no abnormalities.
In November 1992, Bourke 8 reported 3 new cases of
low back pain during streptokinase infusion. In the 3 cases,
the pain was extremely severe and had the characteristics al-
ready cited. In all of them, streptokinase was suspended,
and an endovenous opioid was administered, which resul-
ted in relief of the low back pain in less then 10 minutes.
In 1995, Fishwick et al 9 reported on the case of a 66-
year-old patient with chest pain for 6 hours and an electrocar-
diogram indicating infarction in the posterior wall 9. After in-
fusion of 250,000 U of streptokinase, the patient suddenly de-
veloped severe low back pain. As no neurologic abnormality
or vascular alteration could be detected on physical exa-
mination, the authors replaced streptokinase with a tissue
plasminogen activator. The treatment was completed with no
other incidents, and no further investigation was reported.
On a review of the literature, we found no new cases re-
ported in the last 5 years. Therefore, we conclude that since
the initial report of 3 cases by Shah and Taylor 2, 16 new ca-
ses have been reported. In only 4 patients, streptokinase
was maintained after a brief clinical assessment and use of
opioids. In 2 patients, streptokinase was replaced by tissue
plasminogen activator, and the infusion could be maintai-
ned. In the remaining patients, the thrombolytic agent was
suspended, and relief of the low back pain always occurred
in less than 10 minutes, independent of opioid use. This
may serve to differentiate low back pain from aortic dissec-
tion, because the latter does not usually subside spontane-
ously and may be refractory to opioids.
The 2 major differential diagnoses of this event are
aortic dissection and retroperitoneal hemorrhage. The ima-
ging techniques are extremely important for this differentia-
tion, which cannot be made through a simple physical exa-
mination. In an ideal situation, an imaging examination
should be performed prior to the safe reintroduction of the
thrombolytic agent. In the cases in which streptokinase was
reintroduced, no imaging examination was performed. In
our patient, the physical examination remained unaltered,
and the low back pain practically subsided after drug sus-
pension. As we were not able to perform an imaging exami-
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nation, we assessed the risk-benefit ratio and reintroduced
the thrombolytic agent.
In conclusion, based on a literature review, we found
reports of 19 cases of low back pain during streptokinase in-
fusion. No patient died due to this complication. The inci-
dence of this phenomenon is difficult to establish in a relia-
ble manner due to the small number of cases reported.
Further studies are definitely necessary to thoroughly
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assess this phenomenon. What is its pathophysiology?
The theories proposed have not been scientifically evalua-
ted. The entire literature on this subject has been based on
case reports, which makes a more reliable assessment extre-
mely difficult. Therefore, low back pain during streptokinase
infusion is clearly an open question, which requires deeper
studies to better understand this very interesting phenome-
non associated with streptokinase infusion.
